Novel Therapeutic Approaches for MASH
Nov
13
2023
Ballroom BC
-
Hynes Convention Center
8:30
- 10:00 AM EST
Speakers
Description
Abstracts
- Itfg1: A PROMISING TARGET FOR ENHANCED LIVER REGENERATION AND CHRONIC LIVER DISEASE TREATMENT
- TRIPLE HORMONE RECEPTOR AGONIST RETATRUTIDE RESOLVES STEATOSIS IN >85 % OF SUBJECTS WITH MASLD AND OBESITY IN ASSOCIATION WITH IMPROVED METABOLIC HEALTH
- RELATIONSHIP OF NON-INVASIVE MEASURES WITH HISTOLOGICAL RESPONSE IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS: 52-WEEK DATA FROM THE PHASE 3 MAESTRO-NASH TRIAL
- SAROGLITAZAAR IS EFFECTIVE IN IMPROVING LIVER STIFFNESS MEASUREMENT AND LIVER ENZYMES IN NONALCOHOLIC STEATOHEPATITIS
- EMPAGLIFLOZIN IS EQUALLY EFFECTIVE IN REDUCING LIVER FAT CONTENT IN T2DM PATIENTS AND IN NON-DIABETIC INDIVIDUALS, A RANDOMIZED TRIAL
- DEEP PHENOTYPING OF TM6SF2 TO CHARACTERIZE HEPATIC STEATOSIS, PLASMA LIPID TRAITS, AND METABOLIC RISK FACTORS USING A GENOME-FIRST APPROACH